Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Philip

Showing results (471-480 of 521) with videos related to

Pageof 53
Sort By:
NPJ Precision Oncology|September 30, 2024
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancerJingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Pancreas|December 6, 2012
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi processJonathan R Strosberg, George A Fisher, Al B Benson, et al.
Transgenic Research|June 11, 2002
The expression of a mammalian proteinase inhibitor, bovine spleen trypsin inhibitor in tobacco and its effects on Helicoverpa armigera larvaeJohn T Christeller, Elisabeth P J Burgess, Valentina Mett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.
Molecular Cancer Therapeutics|July 13, 2021
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to EverolimusGabriel B Mpilla, Md Hafiz Uddin, Mohammed N Al-Hallak, et al.
Clinical and Translational Medicine|December 22, 2023
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse modelMd Hafiz Uddin, Mohammad Najeeb Al-Hallak, Husain Yar Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008Paul Okunieff, Lisa A Kachnic, Louis S Constine, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
ESMO Open|November 24, 2020
Molecular characteristics of <i>BRCA1/2</i> and <i>PALB2</i> mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.
Pageof 53

Showing results (471-480 of 521) with videos related to

Sort By:
Pageof 53
NPJ Precision Oncology|September 30, 2024
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancerJingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Pancreas|December 6, 2012
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi processJonathan R Strosberg, George A Fisher, Al B Benson, et al.
Transgenic Research|June 11, 2002
The expression of a mammalian proteinase inhibitor, bovine spleen trypsin inhibitor in tobacco and its effects on Helicoverpa armigera larvaeJohn T Christeller, Elisabeth P J Burgess, Valentina Mett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Alok Khorana, et al.
Molecular Cancer Therapeutics|July 13, 2021
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to EverolimusGabriel B Mpilla, Md Hafiz Uddin, Mohammed N Al-Hallak, et al.
Clinical and Translational Medicine|December 22, 2023
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse modelMd Hafiz Uddin, Mohammad Najeeb Al-Hallak, Husain Yar Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008Paul Okunieff, Lisa A Kachnic, Louis S Constine, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2023
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
ESMO Open|November 24, 2020
Molecular characteristics of <i>BRCA1/2</i> and <i>PALB2</i> mutations in pancreatic ductal adenocarcinomaAndreas Seeber, Kai Zimmer, Florian Kocher, et al.
Pageof 53